Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma

被引:9
作者
Kim, Hyeongbin [1 ]
Seo, SangHyuk [1 ]
Kim, Kwanghee [1 ]
Park, Yo-Han [1 ]
An, MinSung [1 ]
Baik, HyungJoo [1 ]
Choi, ChangSoo [1 ]
Oh, SangHoon [1 ]
机构
[1] Inje Univ, Busan Paik Hosp, Dept Surg, Bokgiro 75, Busan, South Korea
关键词
Gastric adenocarcinoma; Human epidermal growth factor receptor 2; Five-year survival rate; Prognostic factors; IN-SITU HYBRIDIZATION; CLINICOPATHOLOGICAL FEATURES; GENE AMPLIFICATION; HER2; EXPRESSION; HER-2/NEU GENE; LARGE-SCALE; CANCER; IMMUNOHISTOCHEMISTRY; MULTICENTER; C-ERBB-2;
D O I
10.1186/s12957-019-1652-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The purpose of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and clinicopathologic factors and overall survival rate in patients who underwent curative gastrectomy for gastric adenocarcinoma. Methods: Among patients who underwent curative gastrectomy for gastric adenocarcinoma at Inje University Paik Hospital from January 2012 to December 2015, 782 patients underwent an immunohistochemical analysis to evaluate HER2 expression levels. Clinicopathologic records that were collected from a gastric cancer database were retrospectively reviewed to identify clinicopathologic factors and survival rates of the patients. Results: HER2 overexpression was detected in 166 patients (21.2%). There was a statistically significant correlation between HER2 expression level and sex (p = 0.013), histologic differentiation (p < 0.001), Lauren classification (p < 0.001), and T pathologic stage (p = 0.022). There were no statistically significant relationships between HER2 expression level and overall 5-year survival rate (p = 0.775) and overall 5-year survival rate of gastric adenocarcinoma classified according to the TNM stage (stage I: p = 0.756, stage II: p = 0.571, stage III: p = 0.704). The HER2 expression level was not affected by the overall 5-year survival rate in the uni- and multivariate analyses. Conclusions: In this study, the HER2 overexpression rate in gastric adenocarcinoma was 21.2% and was observed in well- and moderately differentiated types according to histologic differentiation, intestinal type according to the Lauren classification, male, and low T stage. There was no correlation between HER2 expression level and overall 5-year survival rate, and HER2 expression level was not associated with independent prognostic factors.
引用
收藏
页数:9
相关论文
共 30 条
  • [1] HER2-directed therapy: current treatment options for HER2-positive breast cancer
    Ahmed, Shahid
    Sami, Amer
    Xiang, Jim
    [J]. BREAST CANCER, 2015, 22 (02) : 101 - 116
  • [2] Bang YJ, 2010, LANCET, V376, P1302
  • [3] Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    Bang, Yung-Jue
    Kim, Young-Woo
    Yang, Han-Kwang
    Chung, Hyun Cheol
    Park, Young-Kyu
    Lee, Kyung Hee
    Lee, Keun-Wook
    Kim, Yong Ho
    Noh, Sang-Ik
    Cho, Jae Yong
    Mok, Young Jae
    Kim, Yeul Hong
    Ji, Jiafu
    Yeh, Ta-Sen
    Button, Peter
    Sirzen, Florin
    Noh, Sung Hoon
    [J]. LANCET, 2012, 379 (9813) : 315 - 321
  • [4] Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
    Begnami, Maria D.
    Fukuda, Emy
    Fregnani, Jose H. T. G.
    Nonogaki, Suely
    Montagnini, Andre L.
    da Costa, Wilson L., Jr.
    Soares, Fernando A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3030 - 3036
  • [5] HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
    Brien, TP
    Odze, RD
    Sheehan, CE
    McKenna, BJ
    Ross, JS
    [J]. HUMAN PATHOLOGY, 2000, 31 (01) : 35 - 39
  • [6] Cheung DY, 2013, KOREAN J GASTROENTER, P117
  • [7] Edge S B., 2010, AJCC Cancer Staging Manual, V7th, P117
  • [8] Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer
    He, Chao
    Bian, Xue-Yi
    Ni, Xing-Zhi
    Shen, Dan-Ping
    Shen, Yan-Ying
    Liu, Hua
    Shen, Zhi-Yong
    Liu, Qiang
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (14) : 2171 - 2178
  • [9] Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
    Hofmann, M.
    Stoss, O.
    Shi, D.
    Buettner, R.
    van de Vijver, M.
    Kim, W.
    Ochiai, A.
    Rueschoff, J.
    Henkel, T.
    [J]. HISTOPATHOLOGY, 2008, 52 (07) : 797 - 805
  • [10] Ishikawa T, 1997, AM J PATHOL, V151, P761